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Abstract
Vascular calciﬁcation, occurring during late-stage vascular and valvular disease, is highly associated with chronic kidney
disease-mineral and bone disorders (CKD-MBD), representing a major risk factor for cardiovascular morbidity and mortality.
The hallmark of vascular calciﬁcation, which involves both media and intima, is represented by the activation of cells
committed to an osteogenic programme. Several studies have analysed the role of circulating calcifying cells (CCCs) in vascular
calciﬁcation. CCCs are bone marrow (BM)-derived cells with an osteogenic phenotype, participating in intima calciﬁcation
processes and deﬁned by osteocalcin and bone alkaline phosphatase expression. The identiﬁcation of CCCs in diabetes and
atherosclerosis is the most recent, intriguing and yet uncharted chapter in the scenario of the bone–vascular axis. Whether
osteogenic shift occurs in theBM, the bloodstreamor both, is not known, and also the factors promotingCCC formationhavenot
been identiﬁed. However, it is possible to recognize a common pathogenic commitment of inﬂammation in atherosclerosis and
diabetes, in which metabolic control may also have a role. Currently available studies in patients without CKD did not ﬁnd an
association of CCCs with markers of bone metabolism. Preliminary data on CKD patients indicate an implication of mineral
bone disease in vascular calciﬁcation, as a consequence of functional and anatomic integrity interruption of BM niches. Given
the pivotal role that parathyroid hormone and osteoblasts play in regulating expansion, mobilization and homing of
haematopoietic stem/progenitors cells, CKD-MBD could promote CCC formation.
Key words: atherosclerosis, calcifying circulating cells, chronic kidney disease-mineral and bone disorders, mineral
metabolism, vascular calciﬁcation
Introduction
Cardiovascular disease (CVD) is the leading cause of death
among patients with chronic kidney disease (CKD). The clinical
and pathologic background of CVD in CKD patients is schematic-
ally represented by left ventricular hypertrophy (LVH), cardiac
electrical remodelling (often connected to LVH), arteriosclerosis,
atherosclerosis and valvular disease, the presence of which is
often correlated to the degree of coronary atherosclerosis [1, 2].
Vascular calciﬁcation occurs during the late stage vascular
pathology (arterio/atherosclerotic) and valvular disease. Add-
itionally, vascular calciﬁcation is one of the independent risk
factors associated with cardiovascular morbidity and mortality
of CKD patients.
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Three types of vascular calciﬁcations have been described in
uraemia: (i) classical calciﬁed atherosclerotic plaque, (ii) arterial
media calciﬁcation (mediacalcinosis or Monckeberg’s disease)
and (iii) cardiac valvular calciﬁcations. However, this does not ex-
clude the possibility of distinct types of vascular calciﬁcations
concurring in the same patient. Indeed CKD patients have been
shown to have vascular calciﬁcations involving not only the
media but also the intima, the latter being associated with re-
duced renal function [3].
A crosstalk exists between the bone and the vasculature,
which is commonly referred to as the bone–vascular axis, the
pathological expression ofwhich is the close association between
bone turnover, vascular calciﬁcation and cardiovascular events
either in general population or in patients with CKD [4–6].
Several studies suggest that in CKD patients, the disorders of
bone and mineral metabolism, commonly known as CKD-min-
eral and bone disorder (CKD-MBD), together with inﬂammation
and oxidative stress are implicated in the pathogenesis of vascu-
lar calciﬁcation [7]. For decades, vascular calciﬁcation has been
considered a passive phenomenon, intrinsically connected
with ageing and atherosclerotic vascular degeneration.
However, a series of clinical and basic science studies per-
formed in the last several years underscored the biological com-
plexity of the processes driving ectopic mineralization, the main
hallmark of which is the activation of an osteogenic programme
with the acquisition by the cells involved of an osteogenic pheno-
type. Vascular calciﬁcation is thought to develop inside the
vascular wall with two seminal events leading to their formation:
(i) a disequilibrium between protective and promoting factors of
calciﬁcation pathways and (ii) the differentiation of parietal cells
into chondrocyte/osteoblast-like cells.
However, while activating a common osteogenic programme,
the factors involved in intima and media calciﬁcation are not
identical.
It is well known that resident vascular cells produce local
mediators, such as pyrophosphate and matrix-Gla protein that,
in cooperation with circulating molecules (i.e. fetuin-A), protect
the arteries from vascular calciﬁcation [8–10]. Several factors
regulate, either promoting or inhibiting, vascular calciﬁcation
pathways, namely imbalances in serum calcium and phosphate,
parathyroid hormone (PTH), FGF23, Klotho, systemic inﬂamma-
tion, RANK/RANKL/OPG signalling, Wnt inhibitors and osteocal-
cin (OC) [11–13].
In addition, cells showing morphological and biological fea-
tures close to chondrocyte/osteoblast-like cells have been identi-
ﬁed in intimal andmedial calciﬁcations, of bothmousemodels of
atherosclerosis and human atherosclerotic samples, although
with a different impact depending on the location of calciﬁcation
(intima, media and valvular) [14, 15]. These cells might originate
from several sources, including vascular wall-resident mesen-
chymal stem cells (MSCs), transdifferentiation of mature vascu-
lar smooth muscle cells (SMCs) or circulating calcifying cells
(CCCs), even though there is poor evidence for a contribution of
CCCs in medial calciﬁcation [16].
A growing number of studies are shedding light on how CCCs,
cells deriving from bone marrow (BM) differentiated towards an
osteogenic phenotype, engraft into the pathological tissue and
participate in calciﬁcation processes that take place in the intima.
An important issue is to fully elucidate the role of CCCs in the
pathogenesis of vascular calciﬁcation. Therefore, the term CCC
identiﬁes several osteogenic cell subsets, expressing different but
interrelated phenotypes, sharing a common origin from BM pro-
genitor cells and able to promote intimacalciﬁcation, so represent-
ing a further and complex aspect of the bone–vascular axis.
The role of BM in vascular health
An understanding of the pathophysiological processes linked
to the presence of the CCCs cannot be separated from an analysis
of the factors involved in regulating the passage, from BM into the
bloodstream, of haematopoietic stem/progenitor cells (HSPCs)
that are committed or not towards different cell lineages.
In adulthood, BM is the major reservoir for HSPCs since a
specialized microenvironment (niche) hosts and modulates
their renewal and egress in the bloodstream. Inside the niche, a
complicate interplay that involves solublemediators and surface
cell receptors regulates the HSPCs number, fate and location.
Moreover, current data suggest the existence of specialized
niches for distinct types of haematopoietic stem and progenitor
cells [17].
The BM niche consists of two major elements. The ﬁrst is the
osteoblastic niche that maintains HSPCs, keeping them quiescent
for its self-renewal. The second element is the vascular niche,
composed of vascular sinuses, lining endothelial cells, nestin-
positive CXCL12-abundant reticular (CAR) cells, sympathetic neu-
rons and haematopoietic stem cells. Inside the vascular niche,
HSPCs are activated for proliferation and vascular/tissue repair
[18, 19].
Under normal and pathological conditions, there is continuous
egress out of the BM into the bloodstream of HSPCs, including
those committed towards a speciﬁc lineage: endothelial and
monocytic, osteoprogenitors (MSC), perivascular cells (i.e. peri-
cytes and SMCs), endothelial progenitor cells (EPCs) andprecursors
of interstitial valve cells: this process is termed mobilization [20,
21]. Besides, homing is a set of complex mechanisms that modu-
late the mobilization towards distant BM niches in the periphery
and peripheral (vascular) tissues. Mobilization and homing are
mirror processes depending on the interactions between cyto-
kines, erythropoietin, growth factors, hormones and match
receptors cells inside the niche [20].
While osteoblastic cells regulate the haematopoietic stem cell
frequency and renewal, inside the niche PTH plays the role of piv-
otal director of the HSPCs microenvironment through activation
of PTH/PTHrP receptors (PPRs) [22]. PPR-stimulated osteoblastic
cells produce high levels of the Notch ligand jagged 1 (a Notch lig-
and), and activated Notch signalling elicits a further increase in
the number of HSPCs [23]. PTH-driven HSPCs expansion is also
mediated by the upregulation of cytokines like IL-6, IL-11 and
granulocyte colony-stimulating factor (GCSF) that controls, in
its turn, the CXCL12 expression in different cell types. CXCL12,
also called SDF-1, is the key chemokine inmobilization and hom-
ing processes. CXCL12 expression in osteoblasts, endothelial
cells, BM, heart, skeletal muscle, liver and brain is regulated by
PTH, the sympathetic nervous system and GCSF [17, 24]. The
interaction between CXCL12 and the homing receptor CXCR-4,
which is expressed on many progenitors, circulating or not, is
the most important mechanism for both retaining HSPCs within
the BM and their mobilization [25–27]. Inside the niche, osteo-
blasts regulate and ensure the renewal of HSPCs since they ex-
press CXCL12, so binding HSPCs that are primarily quiescent
[19]. PTH drives the expansion of HSPCs in the BM either directly
or through stimulation of GCSF,which in turn, through the loss of
osteoblasts and lowering of CXCL12 expression by the cells inside
the niche, fosters the transmigration of HSPCs into the vascular
sinuses (Figure 1). PTH promotes the homing in both normal
and pathological peripheral tissue by inducing an increased ex-
pression of CXCL12 through the downregulation of dipeptidyl-
peptidase IV [21]. Indeed endosteal calcium concentration (near
to resorbing osteoclasts), active on calcium sensing receptor



























(CASr) expressed on HSPCs, regulates their lodging in the BM, but
little is known about the effect of calcium serum levels [28].
Therefore, any factor able to deplete osteoblasts, impair bone
metabolism and/or reduce the expression of CXCL12 results in
impairment of transmigration of HSPCs and derived cell lineages
into the vascular sinuses and then into the circulation [19, 21].
It is through this complex regulatory network that the BM en-
suresmobilization into the bloodstreamof BM-derived cells, such
as EPCs or precursors of resident interstitial valve cells, in order to
maintain the morphological and functional integrity of the ves-
sels and valves.
In this framework, it is not surprising that interruption of the
dynamic anatomy of the niche as well as any changes in BM
microenvironment or in HSPCs function can result in a failure
of theirmobilization (‘mobilopathy’) or in an alteration of cellular
differentiation processes. These modiﬁcations are observed es-
pecially in the course of diabetes. In the BM of diabetic patients,
GCSF lowers osteoblast number and their CXCL12 expression,
leaving unchanged the CXCL12 expression in CAR cells, resulting
in a decreased mobilization of haematopoietic stem cells [19].
The ‘mobilopathy’ can extend to the reduction of HSPCs until
the appearance of progenitors or cell subsets endorsed of an
osteogenic phenotype, which is the hallmark of the CCC [18].
The circulating calcifying cells
The BM mesenchymal and haematopoietic compartments re-
present the sanctuaries that may give rise to HSPCs from which
the pool of CCC originates. Regardless of the type of BM progeni-
tor cell, CCCs are deﬁned by OC and bone alkaline phosphatase
(BAP) expression.
OC is a noncollagenous bone protein implicated in bonemin-
eralization and calcium homeostasis, and BAP is a glycoprotein
found on the surface of osteoblasts that is essential to the min-
eralization process [12, 29].
The pool of CCCs includes circulating (mesenchymal) osteo-
progenitor cells, circulating calcifying EPCs and myeloid calcify-
ing cells [16] (Figure 2).
Circulating (mesenchymal) osteoprogenitor
cells
Although the presence of CCCs has been documented in patients
with diabetes and vascular disease, these cells can be also found
in healthy subjects andmay therefore be regarded, within certain
limits, as a ‘physiological phenomenon’ related to ageing, bone
remodelling or bone healing after fractures.
The precursors of osteoblasts can be found as circulating os-
teoprogenitors in the bloodstream, and they consist of two popu-
lations, one related to MSCs and the other to haematopoietic
stem cells/EPCs. These cells contribute to bone health by partici-
pating in bone remodelling. The appearance of MSC-derived
circulating osteoprogenitors takes place after fracture. Their mo-
bilization into the circulation in response to fracture occurs at
any age, but with a higher frequency in young patients [16].
Circulating osteoprogenitors may also arise from haemato-
poietic stem cells expressing CD34 and CD133 antigens (markers
of stemness) and able to differentiate into endothelial cells and
osteoblasts in vitro. Similarly, in addition to improving bone vas-
cularization, EPCs can undergo procalciﬁc differentiation. This
cell plasticity may ensure an adequate blood supply to bone frac-
ture sites that is crucial for healing process. This ﬁnding, sup-
ported by the recruitment of CD34+ progenitors and endothelial
cells to the fracture sites, reinforces the idea of a tight link be-
tween osteogenesis and vasculogenesis and raises the possibility
that under pathological conditions, haematopoietic stem cells or
Fig. 1. PTH is a pivotal regulator of BM niche and hematopoietic stem cells/circulating precursor cells expansion and mobilization. In the BM, PTH binds to parathyroid
hormone 1 receptor (PTH1R) on osteoblasts and drives the expansion of HSPCs. In addition, GCSF inhibits CXCL12 expression, thus promoting HSPC transmigration into
the vascular sinuses and so into the bloodstream.



























EPCs may be activated, disclosing a procalciﬁc differentiation
capacity [30, 31].
Calcifying endothelial progenitor cells
EPCs are a subgroup of bloodmononuclear cells derived fromBM,
which circulate, proliferate and differentiate into mature endo-
thelial cells. They are involved in angiogenesis and vessel repair.
While several putative EPC phenotypes with different lineages
and function have been identiﬁed, true EPCs are supposed to de-
rive from HSPCs. EPCs descending from this lineage should ex-
press both stemness markers, CD34 and CD133, and endothelial
markers such as vascular endothelial growth factor receptor-2
(VEGFR-2). Coexpression of the stem cell antigen CD133 increases
speciﬁcity for EPCs because it is not expressed by mature endo-
thelial cells [32–34]; additionally, the lack of CD45 (CD45−),
which is generally considered a speciﬁc pan-leukocyte marker,
identiﬁes cell phenotypes restricted to endothelial lineage [32].
Flow cytometry is the gold standard for the classiﬁcation of
EPC subsets (based on expression of the surface markers) and
for their assessment as cardiovascular biomarkers [32]. As de-
scribed earlier, EPCs are able to undertake differentiation towards
both vascular and bone phenotypes. Recent data have demon-
strated that circulating CD34 progenitor cells and CD34+/VEGFR-
2+ EPCs can express bone-related proteins, in particular OC and
BAP, the markers of osteogenic phenotype. Calcifying circulating
EPCs have been associated with coronary artery disease, coron-
ary endothelial dysfunction, calciﬁc aortic stenosis and diabetes,
although their presence in the bloodstream is minimal (0.01%).
An increase of calcifying circulating EPCs is associated with the
reduction of circulating CD34+/VEGFR-2+ EPCs in Type 1 diabetes
but not in CAD [35–37].
In CKD, many factors have been identiﬁed as potential trig-
gers of endothelial dysfunction [38], but poor data are currently
available on the quantitative and qualitative changes in EPC as
well as on the presence of circulating calcifying EPC in CKD pa-
tients. Although there is a general consensus that CKD-MBD, in-
ﬂammation and hyperglycaemia all exert pivotal roles, the
presence of additional factors potentially promoting an osteo-
genic shift are still undeﬁned. It is well established that osteo-
blasts and PTH are critical regulators of HSPCs expansion and
mobilization into the bloodstream and that EPCs and endothelial
cells can express vitamin D receptor (VDR), PTH receptor and cal-
cium-sensing receptor. Moreover, vitamin D has been proven to
have a beneﬁcial effect in restoring EPC number and function im-
pairment observed in diabetic and CKD patients [39–41]. The role
of FGF23 and Klotho on these cells is not known: an evaluation of
the effects of these molecules would be appropriate given their
putative impact on the vascular calciﬁcation process.
We have previously reported that CKD patients have an high-
er relative count of CD34+/CD133−/VEGFR-2+/CD45− cells expres-
sing OC compared with healthy subjects [42].
The presence of circulating EPCwith an osteogenic phenotype
provides insights into the paradox of a calcifying stimulus origin-
ating from cells that normally exert a vasoprotective role.
Circulating myeloid calcifying cells
Cells belonging to the myeloid lineage (monocytes–macrophages),
are characterized byanextreme phenotypic variability. These cells
can exist in different states of activation: pro-inﬂammatory (M1)
and anti-inﬂammatory (M2), with opposite effects on inﬂamma-
tion, tissue remodelling and angiogenesis.
In particular, M2monocytes–macrophages support angiogen-
esis and are identiﬁed by expression of the angiopoietin receptor
TIE2 [43, 44].
Fadini et al. [45] demonstrated that a fraction of circulating
monocytes (∼1% in healthy adults) express BAP and OC driven
Fig. 2.The pool of CCCs includes osteoprogenitor (mesenchymal) cells, calcifying EPCs andmyeloid calcifying cells. The termCCC identiﬁes several osteogenic cell subsets
expressing different yet partly interrelated phenotypes that have a common origin from BM progenitor cells. CCCs are involved in osteogenesis/angiogenesis and in
intimal calciﬁcation.



























by Runx2, a master regulator of osteogenesis, and proposed the
term ‘calcifying myeloid cells’ (MCCs) for this cell population.
Human MCCs also possess anti-angiogenic properties mediated
by upregulation of the thrombospondin-1, a protein that inhibits
VEGF signalling and angiogenesis, as well as endothelial cell mi-
gration, proliferation and survival. More generally, calciﬁcation
and inhibition of angiogenesis displayed by MCCs may be part
of a late attempt to control inﬂammation [46].
MCCswere found to be signiﬁcantly increased in the presence
of either CVD or diabetes (Type 2) [44]. In addition, MCC numbers
were higher regardless of the coexistence of CVD in diabetic ver-
sus non-diabetic patients, accounting for up to 3–4% of blood
cells, andwere also expanded in the BM (2- to 4-fold higher in dia-
betic BM than in control BM) and atherosclerotic plaques.
However, the studydoesnot prove adirect participationofMCC
in intimal calciﬁcation, but their detection in carotid atherosclerot-
ic specimens from diabetic patients supports this hypothesis.
The mechanisms that trigger MCCs remain to be deﬁned.
Their appearance in diabetic patients is promoted by intima
hypoxia and especially by hyperglycaemia. In this regard, the le-
vels of circulating MCCs in diabetes mellitus are reversible after
optimization of glycaemic control.
Potential role of CCCs in CKD patients
The identiﬁcation of CCCs is undoubtedly the most intriguing,
yet relatively uncharted area in the multifaceted scenario of
the bone–vascular axis. Although their role is not yet fully de-
ﬁned, the detection and recognition of CCCs is a landmark in
the comprehension of vascular calciﬁcation pathogenesis.
Whatever their origin and phenotype, CCCs may engraft to
sites of vascular disease to further promote ectopic calciﬁcation.
However, up to now, there is no clear proof of CCCs actively par-
ticipating in medial calciﬁcation (Figure 3). This is particularly
important considering that the derangement of the bone–
vascular axis is ampliﬁed by ageing, CKD, diabetes and athero-
sclerosis, the incidence of which are constantly rising in the
general population.
There are still limited data available concerning the factors re-
lated to the presence of CCCs, aswell as on the districts where the
osteogenic shift of the involved cell subsets occurs: in the BM or
bloodstream or both.
However, even in various clinical settings, it is possible to
speculate inﬂammation as the shared pathogenetic link, also
bearing in mind that diabetes, atherosclerosis and CKD often
coexist. CCCs aremainly involved in atherosclerotic and valvular
lesions whose progression is interrelated to inﬂammatory me-
chanisms. It is conceivable that, at least in the early stages,
CCCs might be recruited along with resident cells endowed of
osteogenic phenotype in order to deposit calcium in the tissue
in an effort to resolve inﬂammation in the vascular/valve wall.
In diabetes, the degree of metabolic control may have a
signiﬁcant role in regulating the osteogenic shift.
Studies conducted to date (not including CKD patients) failed
to ﬁnd relationships between the presence of CCCs and markers
of bone metabolism. Hypothetically, MBD could play a more ac-
tive role in CKD patients where they are associated with a well-
knowndisruption of bonemicroarchitecture perturbing the func-
tional and anatomic integrity of BM niches.
Given the crucial role that PTH, osteoblasts and MBD play in
regulating HSPCs expansion, mobilization and homing of
HSPCs, the impairment of bone remodelling that is inherent in
CKD-MBD may also foster the development of cell subsets ex-
pressing an osteogenic phenotype (Figure 4). Additional factors
may involve speciﬁc MBD-related receptors (e.g. VDR, PPR andFig. 3. Putative role of CCCs in intimal, valvular and medial calciﬁcation.
Fig. 4. PTH and CCCs in CKD. The putative link between CKD, CCCs and intimal calciﬁcation.



























CaSR) on HSPCs and/or their derangement, that have either com-
mitted or not towards different cell lineage [37–41].
Moreover, even though OC function is still poorly understood,
gene deletion studies seem to indicate a possible contribution in
bone remodelling [12]. OC is produced by osteoblastic cells and
circulating osteoprogenitor cells (i.e. cells of haematopoietic
and mesenchymal origin), and its expression is regulated by a
number of calcitropic hormones and growth factors, including
1,25-dihydroxy vitamin D3, PTH, bone morphogenetic proteins,
tumour necrosis factor α and transforming growth factor β. In
addition, PTH, signalling through PPRs and Runx2, might induce
OC/BAP expression on several cell populations originating from
the BM.
Deﬁning the role of CCCs in the bone–vascular axis will be
important for CKD patients, given the high cardiovascular mor-
bidity and mortality, the increasing prevalence of diabetes and
vascular disease as causes of CKD, and the marked changes in
bone metabolism.
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